Abstract
Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc.
There are no valid biomarkers to predict the occurrence of SSc-ILD, although auto-antibodies against anti-topoisomerase I and several inflammatory markers are candidate biomarkers that need further evaluation. Chest auscultation, presence of shortness of breath and pulmonary function testing are important diagnostic tools, but lack sensitivity to detect early ILD. Baseline screening with high-resolution computed tomography (HRCT) is therefore necessary to confirm an SSc-ILD diagnosis. Once diagnosed with SSc-ILD, patients' clinical courses are variable and difficult to predict, although certain patient characteristics and biomarkers are associated with disease progression. It is important to monitor patients with SSc-ILD for signs of disease progression, although there is no consensus about which diagnostic tools to use or how often monitoring should occur. In this article, we review methods used to define and predict disease progression in SSc-ILD.
There is no valid definition of SSc-ILD disease progression, but we suggest that either a decline in forced vital capacity (FVC) from baseline of ≥10%, or a decline in FVC of 5–9% in association with a decline in diffusing capacity of the lung for carbon monoxide of ≥15% represents progression. An increase in the radiographic extent of ILD on HRCT imaging would also signify progression. A time period of 1–2 years is generally used for this definition, but a decline over a longer time period may also reflect clinically relevant disease progression.
Abstract
Lung function tests and chest imaging help predict who has SSc-associated ILD and whether it will progress. In the absence of standardised methods for doctors, we recommend a strategy that combines both lung function tests and chest imaging.http://bit.ly/2uK9ZD2
Footnotes
Author contributions: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors. They take full responsibility for the scope, direction, content of, and editorial decisions relating to, the manuscript, were involved at all stages of development and have approved the submitted manuscript. The authors received no compensation related to the development of the manuscript. Boehringer Ingelheim International GmbH supported the meeting of the international panel of experts.
个人的利益冲突:o . Distler报告fees for consultancy from Boehringer, during the conduct of the study; grants and personal fees for lectures from Actelion, personal fees for advisory board work from AbbVie, personal fees for consultancy from Acceleron Pharma, Anamar, Amgen, Catenion, CSL Behring, ChemomAb, Ergonex, GSK, Inventiva, Italfarmaco, iQvia, Medac, Lilly, Sanofi, Target BioScience, UCB, Baecon Discovery, Blade Therapeutics, Curzion Pharmaceuticals and Glenmark Pharmaceuticals, grants and personal fees for consultancy and lectures from Bayer and Boehringer Ingelheim, personal fees for lectures from iQone, Menarini, Mepha and Novartis, personal fees for consultancy and lectures from Medscape, MSD and Roche, grants and personal fees for consultancy from Mitsubishi, personal fees for consultancy and lectures and non-financial (travel) support from Pfizer, outside the submitted work; and has a patent US8247389, EP2331143 issued.
Conflict of interest: S. Assassi reports non-financial (writing) support from Boehringer Ingelheim, during the conduct of the study; grants from Biogen Idec and Bayer, grants and personal fees from Boehringer Ingelheim outside the submitted work.
Conflict of interest: V. Cottin reports personal fees for advisory board work and lectures and non-financial (travel) support from Actelion, grants, personal fees for advisory board work and lectures, and non-financial (travel) support from Boehringer Ingelheim and Roche, personal fees for advisory board work and data monitoring committee work from Bayer/MSD and Galapagos, personal fees for data monitoring committee work from Gilead, Celgene and Galecto, personal fees for advisory board work and lectures from Novartis, personal fees for lectures from Sanofi, personal fees for steering committee work and data monitoring committee work from Promedior, outside the submitted work.
利益冲突:m . Cutolo报告授予摇来摇去m Actelion, Boehringer Ingelheim, Horizon, BMS and Celgene, outside the submitted work.
Conflict of interest: S.K. Danoff reports grants and personal fees from Boehringer Ingelheim, grants from Genentech/Roche and Bristol Myers Squibb, personal fees from Galapagos and Galectic, during the conduct of the study.
Conflict of interest: C.P. Denton reports personal fees from Actelion, Bayer, Sanofi, Boehringer Ingelheim and Corbus, grants and personal fees from GlaxoSmithKline, Inventiva, CSL Behring and Leadiant Biosciences, during the conduct of the study.
Conflict of interest: J.H.W. Distler reports personal fees for speaking and advisory board work from Boehringer Ingelheim.
Conflict of interest: A-M. Hoffmann-Vold reports non-financial support from Boehringer Ingelheim, during the conduct of the study; grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Actelion, personal fees from Roche, outside the submitted work.
Conflict of interest: S.R. Johnson reports grants from Boehringer Ingelheim, Corbus, Bayer, Roche and the Canadian Institutes of Health Research outside the submitted work.
Conflict of interest: U. Müller Ladner reports personal fees for advisory board work and lectures from Boehringer Ingelheim, outside the submitted work.
Conflict of interest: V. Smith reports speaker fees from Boehringer Ingelheim, during the conduct of the study; grants from Boehringer Ingelheim, research funding from Actelion Pharmaceuticals Ltd, Bayer AG, Hoffman-La Roche AG, Galapagos NV and Sanofi, outside the submitted work.
Conflict of interest: E.R. Volkmann reports personal fees from Boehringer Ingelheim, outside the submitted work.
Conflict of interest: T.M. Maher reports grants and personal fees from GSK and AstraZeneca, grants, personal fees and non-financial support from UCB, personal fees from Boehringer Ingelheim, Roche, Bayer, Prometic, Samumed, Galapagos, Celgene, Indalo, Pliant, Blade Therapeutics, Respivant, Novartis and Bristol-Myers Squibb, stock options from Apellis, outside the submitted work.
Support statement: S.R. Johnson has been awarded a Canadian Institutes of Health Research New Investigator Award; and is supported by the Oscar and Eleanor Markovitz Fund for Scleroderma Research of the Arthritis Research Foundation. V. Smith is a Senior Clinical Investigator of the Research Foundation – Flanders (Belgium) (FWO) (1.8.029.15N). The FWO was not involved in study design, collection, analysis and interpretation of data, writing of the report, nor in the decision to submit the article for publication. T.M. Maher is supported by a National Institute for Health Research Clinician Scientist Fellowship (NIHR ref: CS-2013-13-017) and is a British Lung Foundation Chair in Respiratory Research (C17-3). Writing, editorial support and formatting assistance was contracted and funded by Boehringer Ingelheim International GmbH. Funding information for this article has been deposited with theCrossref Funder Registry.
- ReceivedOctober 15, 2019.
- AcceptedFebruary 9, 2020.
- Copyright ©ERS 2020
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.